Sentinel lymph node @entity3 in microinvasive XXXX .

@entity1 @entity3821 @entity0 @entity4298 @entity3
BACKGROUND: @entity3821 ( @entity3821 ) is a separate pathological entity, distinct from pure @entity3821 ( @entity3821 ). @entity3821 is a true invasive @entity0 with a well-known metastatic potential. Currently, there is controversy regarding the indication for complete axillary dissection (CAD) to stage the axilla in @entity1 with @entity3821 . The role of CAD is questioned given its morbidity and reported low incidence of axillary involvement. Sentinel lymph node biopsy (SLNB) may obviate the need for CAD in these @entity1 without compromising the staging of the axilla and the important prognostic information. METHODS: From March 1996 to December 2002, 4602 consecutive @entity1 with invasive @entity0 underwent @entity4298 biopsy. Of these, 41 @entity1 with @entity3821 were selected. RESULTS: @entity3 in the @entity4298 were detected in 4 of 41 (9.7%) @entity1 . Two of the 4 @entity1 had only micrometastasis in the @entity4298 . In three @entity1 , the @entity4298 was the only positive node after CAD. CONCLUSIONS: @entity4298 biopsy should be considered as a standard procedure in @entity3821 @entity1 . SLNB can detect nodal micrometastasis and accurately stage the axilla avoiding the morbidity of a CAD. Complete AD may not be mandatory if only the @entity4298 contains micrometastatic disease. Informed consent is very important in the decision not to undergo CAD.
